Highlights

  • The third quarter 2026 net loss was $10,091 thousand, or $0.05 per share, compared with $6,791 thousand a year earlier.
  • On November 17, 2026, SELLAS announced the REGAL study met its primary overall survival endpoint, with hazard ratio 0.59.
  • Cash and cash equivalents were $134,711 thousand at September 30, 2026 and $71,793 thousand at December 31, 2025.
  • The company received approximately $85.1 million from the exercise of 50.4 million warrants during the first nine months of 2026.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) shares were trading at USD 18.67 on November 17, 2026, up 149.93%, with a relative Volume at time of 17.54. The late-stage cancer company said on October 28, 2026 that the REGAL study had reached its event threshold, filed its Quarterly Report on November 12 and announced REGAL study results on November 17.

SELLAS is a Delaware corporation with principal executive offices at 7 Times Square in New York. It describes itself as a late-stage clinical biopharmaceutical company focused on novel therapeutics for a broad range of cancer indications. Its lead product candidate, galinpepimut-S, or GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein. Its second candidate, SLS009, is a CDK9 inhibitor licensed from GenFleet Therapeutics. The company does not currently generate revenues.

Third Quarter Results

For the third quarter ended September 30, 2026, SELLAS reported a net loss of $10,091 thousand, or $0.05 per share, compared with a net loss of $6,791 thousand, or $0.06 per share, in the third quarter of 2025. Research and Development expenses were $7,029 thousand, compared with $4,216 thousand.

For the nine months ended September 30, 2026, the net loss was $28,103 thousand, or $0.15 per share, compared with $19,205 thousand, or $0.20 per share. Total operating expenses were $31,190 thousand, compared with $20,019 thousand.

Pipeline and Clinical Updates

REGAL is an open-label randomized Phase 3 study of GPS monotherapy in patients with acute myeloid leukemia in the maintenance setting after second complete remission. Its primary endpoint is overall survival. On October 28, 2026, the company announced that the pre-specified threshold of 80 events had been reached, triggering the final analysis. On November 17, 2026, the company announced that REGAL met its primary overall survival endpoint. The Vaccine showed a 41% reduction in risk of death (hazard ratio 0.59, p=0.035), and median survival was 24.0 months versus 14.7 months for BAT, the comparator arm. Safety was consistent with prior data. The company plans to meet with the FDA on an accelerated filing strategy and to prepare a BLA submission in the first half of 2027.

The company announced in November 2026 that data from its completed Phase 2 study of SLS009 will be presented at the 68th American Society of Hematology Annual Meeting. A randomized Phase 2 trial of SLS009 in newly diagnosed, first-line acute myeloid leukemia, which began enrolling in the first quarter of 2026, had enrolled 40 patients as of November 5, 2026.

Balance Sheet, Cash Flow and Capital

Cash and cash equivalents were $134,711 thousand at September 30, 2026, compared with $71,793 thousand at December 31, 2025. The accumulated Deficit was $303.1 million.

Net cash used in Operating Activities was $22,374 thousand for the nine months, and net cash provided by financing activities was $85,292 thousand. The company received approximately $85.1 million from the exercise of 50.4 million warrants at a weighted average exercise price of $1.69 per share.

In March 2026, SELLAS entered into a sales agreement with TD Securities (USA) LLC to sell common stock of up to $150.0 million in gross proceeds through an at-the-market program. It has not sold any shares under the program.

Liquidity and Outlook

The company evaluated conditions under Going Concern accounting guidance and said it expects its cash and cash equivalents to be sufficient to fund current planned operations for at least the next twelve months from the date the financial statements were issued. It said it may pursue additional capital, and that some financings could be dilutive to existing stockholders.

SELLAS said it expects operating losses and negative cash flows from operations for the next few years and will need additional funding. It expects research and development expenses to increase for the foreseeable future.